In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergent Europe

Division of Emergent BioSolutions Inc.
www.microscience.com

Latest From Emergent Europe

Drug Delivery Spin-Off Adds OTC

Vectura, focused on pulmonary drug delivery, has created a spin off which assembles the oral and dermal technologies it had already de-prioritized, with two enabling technologies from Unilever. PharmaKodex Ltd. will develop OTC drugs as a fast route to market, followed by Rx products using the same technologies.
BioPharmaceutical Strategy

European Financing: The Money's Back, But How Do You Get It?

Two of Europe's handful of IPOs this season are struggling to stay afloat. Bankruptcies continue among private German biotechs. Yet VCs have more money than ever and two of the European biotech flotations were the second- and third-largest globally during this window. What do Europe's biotechs need to do in this new, cautious and contradictory era in order to raise private funds and survive on the open markets? In Vivo Europe Rx asked three top leading European financiers.
BioPharmaceutical Europe

Microscience IPO: With a Little Help From Its Friends

Unusually, the VC investors in UK-based Microscience have announced they will pump a further £10 million into the vaccine developer as it tries to enter the lukewarm public markets with a summer IPO on London's AIM. With underwhelming debuts from Ark Therapeutics and Basilea Pharmaceutica in Europe and dramatically reduced offering prices in both Europe and the US, Microscience's investors' show of solidarity may make a necessary difference. But in the end, it's still all about the valuation.
BioPharmaceutical Europe

Recent Dealmaking (07/2004)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Microscience Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Emergent BioSolutions Inc.
  • Senior Management
  • Steven Chatfield, PhD, CEO
  • Contact Info
  • Emergent Europe
    Phone: (44) 118 944 3300
    545 Eskdale Rd. Winnersh Triangle
    Wokingham, RG41 5TU
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register